Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 7/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | FABP6 | P51161 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14235252 | 0.88 | CFTR (1.00) | CFTRKMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL16139269 | 0.88 | CFTR (0.64) | CFTRKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL16141421 | 0.88 | CFTR (0.77) | CFTRKMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL14235251 | 0.76 | CFTR (1.00) | CFTRKMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL9763711 | 0.74 | PKM (0.74) | KMT2AALDH1A1KDM4ESMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL1596692 | 0.72 | PKM (0.72) | KMT2AALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL14235359 | 0.72 | CFTR (1.00) | CFTRKMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1108658 | 0.71 | KDM4E (0.62) | KMT2AALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL9640576 | 0.70 | KMT2A (0.67) | KMT2AALDH1A1SMN1; SMN2MEN1MAPT | |
| SCHEMBL29875785 | 0.70 | MAPT (0.67) | KMT2AALDH1A1SMN1; SMN2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073863-B2 | Cyanoquinoline compounds having activity in correcting mutant-CFTR processing and increasing ion transport and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140296215-A1 | Cyanoquinoline Compounds Having Activity in Correcting Mutant-Cftr Processing and Increasing Ion Transport and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296215-A1 | Cyanoquinoline Compounds Having Activity in Correcting Mutant-Cftr Processing and Increasing Ion Transport and Uses Thereof | CFTR, SLC47A1, SLC47A2 | CFTR 1/4885KMT2A 3901/4885ALDH1A1 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.